Wealthcare Advisory Partners LLC Buys New Stake in Insmed, Inc. $INSM

Wealthcare Advisory Partners LLC purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,672 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. grew its position in Insmed by 2.3% in the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after acquiring an additional 475,832 shares in the last quarter. State Street Corp grew its position in Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares in the last quarter. RTW Investments LP raised its stake in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after purchasing an additional 1,758,321 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Insmed by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after purchasing an additional 539,625 shares during the period.

Insider Buying and Selling

In other news, CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the sale, the chief executive officer directly owned 259,058 shares in the company, valued at approximately $30,413,409.20. This represents a 3.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the sale, the insider directly owned 37,648 shares in the company, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 294,440 shares of company stock valued at $37,758,548 over the last quarter. Company insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on INSM shares. Royal Bank Of Canada decreased their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Guggenheim cut their price target on Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. Mizuho set a $192.00 price objective on Insmed in a report on Tuesday, June 16th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $175.00 target price on shares of Insmed in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $205.52.

Insmed Stock Down 2.1%

INSM stock opened at $123.74 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75. The firm has a fifty day moving average price of $107.88 and a two-hundred day moving average price of $128.20. The firm has a market cap of $27.02 billion, a price-to-earnings ratio of -30.11 and a beta of 0.81.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same period in the prior year, the company earned ($1.70) earnings per share. The firm’s revenue was up 296.1% compared to the same quarter last year. Research analysts predict that Insmed, Inc. will post -1.83 EPS for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.